An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan
Psychiatry and Clinical Neurosciences Sep 28, 2017
Ichikawa H, et al. - The long-term safety and efficacy of aripiprazole in treating irritability in pediatric patients (6-17 years) with autistic disorder (AD) in Japan were evaluated. In the long-term treatment of irritability associated with AD in Japanese pediatric patients, aripiprazole was generally safe, well tolerated and effective.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
